Totus Medicines closes $66M Series B to fund early-stage PI3Ka inhibitor, names new CEO
Small molecule biotech Totus Medicines has closed a $66 million Series B to carry its PI3Kα inhibitor through Phase Ia and has named Nassim Usman as its new president and CEO.
The Emeryville, CA-based Totus, which emerged with a $40 million Series A in December 2021, closed the Series B in recent weeks after Usman joined, he told Endpoints News. He replaces founding CEO Neil Dhawan, who will remain as chief scientific officer and add on head of R&D responsibilities, Totus said Friday morning.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.